ANDRESHIA BROOKS: Open Payments
NPI 1093571242 · DANVILLE, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$420 in 22 payments from 11 companies in 2025. Trend: 2023 $0 · 2024 $220 · 2025 $420
Food & beverage: $420
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 3 | $60 |
| Lilly USA, LLC | 3 | $52 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $47 |
| Novo Nordisk Inc | 2 | $44 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $43 |
| Otsuka America Pharmaceutical, Inc. | 2 | $41 |
| Abbott Laboratories | 2 | $39 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $30 |
| AstraZeneca Pharmaceuticals LP | 2 | $29 |
| Exact Sciences Corporation | 1 | $19 |
Products named: MOUNJARO, CAPLYTA, VRAYLAR, Ozempic, XIFAXAN, REXULTI, FREESTYLE LIBRE 3, Kerendia.
Industry payments across VA — which companies pay providers there.
